To the Editor:
Methoxyflurane (MEOF) is a fluorinated hydrocarbon anesthetic that was introduced to the market by Abbott Laboratories as Penthrane in the early 1960s. MEOF was found to have analgesic properties at subanesthetic doses. A disposable inhaler was developed for self-administration of MEOF for pain relief in minor surgical procedures and obstetrics in the late 1960s. In 1966, the first report of postoperative nephrotoxicity associated with MEOF emerged. Although MEOF has been withdrawn for use as an anesthetic agent, low-dose MEOF delivered via a handheld inhaler has continued to be in wide use in Australia and New Zealand since 1975. MEOF as an analgesic has been used by more than 6 million people over the course of 40 y in Australia and New Zealand. Common nonserious adverse effects are reactions such as headache, nausea, dizziness, and somnolence. Generally, adverse effects are mild and transient, resolving after inhalation is stopped. MEOF administered at analgesic doses via a disposable inhaler has recently become available in Europe for emergency treatment of moderate-to-severe pain in conscious adult trauma patients.
A recent study demonstrates that prehospital pain management is characterized by ongoing oligoanalgesia owing to undelivered analgesia.
1
Data from the control arms of the studies that compared MEOF to standard treatment revealed that trauma pain is often undertreated in current clinical practice, and there is no established standard of care. In the first randomized trial of MEOF in the emergency setting in Europe, only 23% of patients with severe pain (>7 on the numeric rating scale) received opioids in the standard-of-care arm or as a rescue medication.2
This was also reported in a French study in which 31 patients, 18% of the control arm, did not achieve pain control.- Borobia A.M.
- Collado S.G.
- Cardona C.C.
- Pueyo R.C.
- Alonso C.F.
- Torres I.P.
- et al.
Inhaled methoxyflurane provides greater analgesia and faster onset of action versus standard analgesia in patients with trauma pain: a randomized controlled trial in emergency departments.
Ann Emerg Med. 2020; 75: 315-328
3
A growing body of evidence demonstrates that inhaled MEOF is well tolerated and effective in providing rapid onset of analgesia. However, few randomized controlled trials have been carried out regarding the matter. There are now several European randomized trials, summarized in Table 1. It is regrettable that 4 of these 5 trials are sponsored by the same pharmaceutical group; this should encourage great caution in interpreting the results and developing new protocols.
Table 1Summary of inhaled methoxyflurane study design in patients with trauma pain
| Study | Design | Primary endpoint | Conclusion |
|---|---|---|---|
| Coffey et al. (2014) 4 NCT01420159 Medical Developments International | Phase 3 randomized, double blind, multicenter, placebo-controlled trial; United Kingdom;300 patients (149 MEOF) | Change in pain intensity as measured using the VAS from baseline to 5, 10, 15, and 20 min after the start of study drug inhalation | MEOF administered with the inhaler is an efficacious, safe, and rapidly acting analgesic |
| Borobia et al. (2020) 2
Inhaled methoxyflurane provides greater analgesia and faster onset of action versus standard analgesia in patients with trauma pain: a randomized controlled trial in emergency departments. Ann Emerg Med. 2020; 75: 315-328 NCT03256903 Mundipharma Pharmaceuticals | Phase 3b randomized, active-controlled, open-label, parallel-group trial performed in 13 emergency department and 1 out-of-hospital unit;Spain;305 patients (156 MEOF) | Change from baseline in NRS pain intensity score during the first 20 min of treatment and time to first pain relief | MEOF is a nonnarcotic, easy-to-administer, rapid-acting, first-line alternative to currently available analgesic treatments for trauma pain |
| Mercadante et al. (2019) 8
Analgesic efficacy, practicality and safety of inhaled methoxyflurane versus standard analgesic treatment for acute trauma pain in the emergency setting: a randomized, open-label, active-controlled, multicentre trial in Italy. Adv Ther. 2019; 36: 3030-3046 NCT03585374 Mundipharma Pharmaceuticals | Phase 3b randomized, open-label, active-controlled, multicenter trial;Italy;272 patients (136 MEOF) | Change in VAS pain intensity from baseline to 3, 5, and 10 min | MEOF provided superior pain relief compared with standard analgesic treatment in patients with moderate-to-severe trauma pain and may offer a simple, fast, effective, nonopioid treatment option |
| Lim et al. (2020) 5 NCT01887951 | Prospective, phased, cluster-randomized crossover study;Singapore;369 patients (167 MEOF) | Reduction in pain as measured by reduction in NRS at 5, 10, 15, and 20 min after treatment; time taken from arrival at scene to administration of treatment | MEOF was superior to 50 mg intramuscular tramadol in terms of analgesic efficacy, onset of effective analgesia, and speed of administration. It was also associated with better paramedic and patient satisfaction |
| Ricard-Hibon et al. (2020) 3 NCT03798899 Mundipharma Pharmaceuticals | Phase 3b randomized, open-label, multicenter, placebo-controlled trial;France;351 patients (178 MEOF) | Time until pain relief ≤30 mm, as assessed on the VAS | MEOF, initiated by triage nurse as part of a multimodal analgesic approach, is effective in achieving pain relief for trauma patients. This effect was particularly pronounced in the severe pain subgroup |
| Marinangeli et al. (2018) (study still in progress) 6 Mundipharma Pharmaceuticals | Phase 3b prospective, single-arm, multicenter trial;Approximately 200 adult patients with a pain score of at least 4 on the NRS owing to limb trauma who were rescued by HEMS will be enrolled. Patients will receive up to 2×3 mL MEOF, self-administered by the patient by inhalation under medical supervision. Rescue medication will be permitted if required. | ||
HEMS, helicopter emergency medical services; MEOF, methoxyflurane; NRS, numeric rating scale; VAS, visual analog scale.
It would appear that MEOF is an efficacious, safe, and rapidly acting analgesic; is easy to administer as a first-line alternative to currently available analgesics; and is associated with better paramedic and patient satisfaction.
2
,- Borobia A.M.
- Collado S.G.
- Cardona C.C.
- Pueyo R.C.
- Alonso C.F.
- Torres I.P.
- et al.
Inhaled methoxyflurane provides greater analgesia and faster onset of action versus standard analgesia in patients with trauma pain: a randomized controlled trial in emergency departments.
Ann Emerg Med. 2020; 75: 315-328
4
,5
The use of MEOF in hostile environments, where patient mobilization is difficult, is of particular interest because of MEOF’s ease of use and speed of action. To assess whether inhaled MEOF is effective, safe, and practical in treating trauma pain in remote and hostile environments, a prospective, single-arm, multicenter trial was designed. This Italian study is currently ongoing and enrolling approximately 200 patients with single-limb trauma.
6
The first patient was enrolled in March 2019.In prehospital settings, where interventions are performed by a variety of professionals where and physicians may not be present, administration of MEOF is practical, with a safe administration route and rapid onset of action. The inhaler is lightweight, robust, and easy to use, even with gloved hands, and it requires minimal training for effective use. It can be easily transported and stored at a wide range of temperatures (−20 to 40°C). In a case report, MEOF provided rapid, effective analgesia for visceral and procedural pain at an altitude of 4470 m.
7
Currently, treatment is to be supervised by a healthcare professional and is self-administered through patient-controlled analgesia. MEOF may be particularly relevant in patients who are able to self-administer analgesia while isolated in hostile environments.Low-dose MEOF administered via a handheld inhaler has provided well-tolerated, short-term pain relief for trauma patients for many years. The availability of a nonnarcotic, well-tolerated, rapid-acting, and effective treatment option may improve acute trauma pain management. The ease of use of MEOF may make it particularly useful in the management of acute pain in hostile environments. MEOF could be a suitable option in the following situations:
- -For emergency prehospital doctors—more specifically, when involved in mountain rescue
- -For paramedics and mountain rescuers while waiting for the arrival of medicalization or transfer to the hospital
- -For the victim, in the context of self-medication, particularly in isolated environments
To date, several randomized trials support the use of MEOF, and it is probably time to carry out a meta-analysis on this subject.
References
- Undertreatment of acute pain (oligoanalgesia) and medical practice variation in prehospital analgesia of adult trauma patients: a 10 y retrospective study.Br J Anaesth. 2013; 110: 96-106
- Inhaled methoxyflurane provides greater analgesia and faster onset of action versus standard analgesia in patients with trauma pain: a randomized controlled trial in emergency departments.Ann Emerg Med. 2020; 75: 315-328
- Inhaled methoxyflurane for the management of trauma related pain in patients admitted to hospital emergency departments.Eur J Emerg Med. 2020; 27: 414-421
- STOP!: a randomized, double-blind, placebo-controlled study of the efficacy and safety of methoxyflurane for the treatment of acute pain.Emerg Med J. 2014; 31: 613-618
- Comparison of inhalational methoxyflurane and intramuscular tramadol for prehospital analgesia.Singapore Med J. 2020; ([Epub ahead of print])
- Prospective, multicentre trial of methoxyflurane for acute trauma-related pain in helicopter emergency medical systems and hostile environments.Adv Ther. 2018; 35: 2081-2092
- Methoxyflurane for procedural analgesia at 4470 m altitude.Wilderness Environ Med. 2018; 29: 388-391
- Analgesic efficacy, practicality and safety of inhaled methoxyflurane versus standard analgesic treatment for acute trauma pain in the emergency setting: a randomized, open-label, active-controlled, multicentre trial in Italy.Adv Ther. 2019; 36: 3030-3046
Article info
Publication history
Published online: April 07, 2021
Identification
Copyright
©2021 Wilderness Medical Society. Published by Elsevier Inc. All rights reserved.
